DataDave said:

Worth knowing that the injection site changes very little.

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest trajectory ever seen for an anti-obesity agent[1].

Amylin receptor agonism enhances satiety signaling through the area postrema and reduces glucagon secretion. Combined with GLP-1R agonism, this dual mechanism may produce even greater efficacy than current agents.

Early-stage data — interpret with caution. But the trajectory is extraordinary.

DataDave said:

Worth knowing that the injection site changes very little.

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36). Three key modifications enable its pharmacokinetic profile:

1. Aib8 substitution: DPP-4 resistance (prevents enzymatic degradation)
2. Arg34 substitution: improved chemical stability
3. C18 fatty diacid at Lys26: albumin binding → long half-life

These three modifications transform a peptide with a 2-minute half-life (native GLP-1) into one with a 168-hour half-life (semaglutide). A masterclass in peptide engineering.

DataDave said:

Worth knowing that the injection site changes very little.

This answered a question I did not know how to ask. Printing the relevant bit and taking it with me.

Adding the clinical framing, because it changes how the question reads. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

Worth separating that from semaglutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Dr.AddMedPHL said:

The version of this that has an answer is narrower than the version being asked.

Same pattern here, and in the same order. I had assumed I was the exception until I read this.